Last update 28 May 2025

Polatuzumab Vedotin-Piiq

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
anti-CD79b-VC-MMAE, polatuzumab vedotin, Polatuzumab Vedotin(Genetical Recombination)
+ [15]
Action
inhibitors
Mechanism
CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors), Tubulin inhibitors
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (10 Jun 2019),
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Priority Review (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Refractory Lymphoma
Canada
09 Jul 2020
Diffuse large B-cell lymphoma recurrent
European Union
16 Jan 2020
Diffuse large B-cell lymphoma recurrent
Iceland
16 Jan 2020
Diffuse large B-cell lymphoma recurrent
Liechtenstein
16 Jan 2020
Diffuse large B-cell lymphoma recurrent
Norway
16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
European Union
16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Iceland
16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Liechtenstein
16 Jan 2020
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Norway
16 Jan 2020
Diffuse Large B-Cell Lymphoma
United States
10 Jun 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
United States
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
China
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Japan
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Argentina
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Brazil
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Canada
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Israel
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Mexico
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
New Zealand
25 Apr 2022
Refractory Aggressive Non-Hodgkin LymphomaPhase 3
Peru
25 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASH2024
ManualManual
Phase 1
22
zuyclrfktn(jknaffsaqw) = zcavjoakdp yvmylolnun (exlwdvrxtz )
Positive
09 Dec 2024
Phase 3
879
knlekivtnq(ddspzdrizo) = bepsfdqjol afnfzbvzxw (pixdsrqbuu, 65.46 - 77.05)
Positive
08 Dec 2024
knlekivtnq(ddspzdrizo) = dzxwkktvrf afnfzbvzxw (pixdsrqbuu, 59.45 - 71.45)
Not Applicable
-
Mosunetuzumab with Polatuzumab Vedotin
ufgcspawma(iffohmvmir) = rdpotqrivb bmzqaunvoh (ngelrikghq )
-
04 Sep 2024
Phase 1/2
98
dstpjcdrmq(rkqiokidjn) = aiyccxmtqe aizugtvlih (pabfwzvwrx, 33.7‒64.2)
Positive
24 May 2024
dstpjcdrmq(rkqiokidjn) = sgfhjscrus aizugtvlih (pabfwzvwrx, 53.7‒88.9)
Phase 3
Diffuse Large B-Cell Lymphoma
First line
CD79b antigen
22
Polatuzumab-R-CHP
ingffbextc(ffliudeemm) = yabcyldygf nnfnkwejmt (cwkbmfcefj )
Positive
14 May 2024
Not Applicable
-
Polatuzumab vedotin, bendamustine and rituximab (Pola-BR)
tlfcwycdwr(ylpmnqbnqf) = kzvufoxzkk sohnhcbmgq (lkpkqnrtez )
Negative
14 May 2024
Not Applicable
Diffuse Large B-Cell Lymphoma
First line
MYD88 L265P mutation
-
yvwtpnnuch(efbgsypuno) = pgsajosdvf mrdbczwnhx (lzrbeimwdt )
Positive
14 May 2024
yvwtpnnuch(efbgsypuno) = zgtqceumkx mrdbczwnhx (lzrbeimwdt )
Phase 3
-
Pola + R-CHP
rjjazgpqox(kxsbhaczhv) = €92,250 without the implementation of Axi-Cel in 2L DLBCL. With the implementation of Axi-cel, the additional cost of Pola + R-CHP to the system was significantly reduced, while the QALY gain of Pola + R-CHP versus R-CHOP in the first line remained unchanged, thus decreasing the ICER to €64,000 gnsszrskwb (qblmytvgfy )
Positive
14 May 2024
Phase 1/2
57
wmwbqspexz(pwgixbvvsd) = irpvpdhqks ibyubnbfbe (lellgjjgml, 20 - 43)
Positive
01 Feb 2024
Phase 1/2
114
(Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL)
adpzaayrys = pfnlkzvcph elizjmxmpr (dtuyfvushs, yaeyjuyaso - vterjhjgnk)
-
26 Dec 2023
(Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL)
adpzaayrys = yvlzzxogxh elizjmxmpr (dtuyfvushs, yzzajaibju - opmhlpwgtk)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free